Abiopharma

🔍 Bacher Desiree (Executive)

Company: LINDE PLC (LIN)

Report Date: 2026-03-09

Detailed Transactions and Holdings:

• Acquired 727 shares of Ordinary Shares (Direct)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 866.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 228 shares of Ordinary Shares at $484.74 per share (Direct)
  Date: 2026-03-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 638.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 260 shares of Ordinary Shares (Direct)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 898.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 82 shares of Ordinary Shares at $484.74 per share (Direct)
  Date: 2026-03-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 816.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 260 shares of Ordinary Shares (Direct)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,076.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 97 shares of Ordinary Shares at $484.74 per share (Direct)
  Date: 2026-03-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 979.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 727 shares of Performance Share Units (ROC) (Derivative)
  Date: 2026-03-09 | Code: A | Expires: 2026-03-07 | Exercise: 2026-03-07 | equity_swap_involved: 0 | shares_owned_after: 727.00 | transaction_form_type: 4 | Footnotes: F4, F5, F5
• Sold 727 shares of Performance Share Units (ROC) (Derivative)
  Date: 2026-03-09 | Code: M | Expires: 2026-03-07 | Exercise: 2026-03-07 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F5, F5
• Acquired 260 shares of Performance Share Units (RTSR) (Derivative)
  Date: 2026-03-09 | Code: A | Expires: 2026-03-07 | Exercise: 2026-03-07 | equity_swap_involved: 0 | shares_owned_after: 260.00 | transaction_form_type: 4 | Footnotes: F4, F6, F6
• Sold 260 shares of Performance Share Units (RTSR) (Derivative)
  Date: 2026-03-09 | Code: M | Expires: 2026-03-07 | Exercise: 2026-03-07 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F6, F6
• Acquired 503 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 503.00 | transaction_form_type: 4 | Footnotes: F4, F7, F7
• Sold 260 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F10, F10
• Acquired 4,098 shares of Stock Options (right to buy) at $483.62 per share (Derivative)
  Date: 2026-03-09 | Code: A | Expires: 2036-03-09 | equity_swap_involved: 0 | shares_owned_after: 4,098.00 | transaction_form_type: 4 | Footnotes: F11
• Holds 309 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: H | shares_owned_after: 309.00 | Footnotes: F4, F8, F8
• Holds 300 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: H | shares_owned_after: 300.00 | Footnotes: F4, F9, F9
• Holds 2,168 shares of Stock Options (right to buy) at $468.77 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2035-03-07 | shares_owned_after: 2,168.00 | Footnotes: F12
• Holds 1,920 shares of Stock Options (right to buy) at $465.29 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2034-03-07 | shares_owned_after: 1,920.00 | Footnotes: F13
• Holds 1,690 shares of Stock Options (right to buy) at $354.14 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2033-03-07 | shares_owned_after: 1,690.00 | Footnotes: F14
• Holds 62 shares of Deferred Stock Units (Derivative)
  Date: 2026-03-09 | Code: H | shares_owned_after: 61.64 | Footnotes: F4, F15, F15

Footnotes:

• F1: Ordinary shares acquired pursuant to the payout of a performance share unit ("PSU") grant made on March 7, 2023.
• F2: Ordinary shares withheld from the payout to cover tax withholdings.
• F3: Ordinary shares acquired pursuant to the payout of a restricted stock unit ("RSU") grant made on March 7, 2023.
• F4: Conversion to Linde plc Ordinary Shares is on a one-for-one basis.
• F5: The PSU paid out on March 9, 2026, and the number of shares awarded and paid out was determined based upon the average annual return on capital ("ROC") of Linde plc from 2023-2025 measured against ROC goals set by the Human Capital Committee of the Board of Directors when the PSU was granted on March 7, 2023.
• F6: The PSU paid out on March 9, 2026, and the number of shares awarded and paid out was determined based upon the relative total shareholder return ("RTSR") of Linde plc from 2023-2025 measured against TSR goals set by the Human Capital Committee of the Board of Directors when the PSU was granted on March 7, 2023.
• F7: Restricted Stock Units that will vest in full and payout on or about March 9, 2029 in Linde plc Ordinary Shares on a one-for-one basis.
• F8: Restricted Stock Units that will vest in full and payout on or about March 7, 2028 in Linde plc Ordinary Shares on a one-for-one basis.
• F9: Restricted Stock Units that will vest in full and payout on or about March 7, 2027 in Linde plc Ordinary Shares on a one-for-one basis.
• F10: Restricted Stock Units that vested in full and paid out on March 9, 2026, in Linde plc Ordinary Shares on a one-for-one basis.
• F11: This option vests over three years in three consecutive equal annual installments beginning on March 9, 2027.
• F12: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2026.
• F13: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2025.
• F14: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2024.
• F15: Deferred stock units acquired under the Linde Compensation Deferral Plan ("Plan"). The deferred stock units will payout in Linde plc Ordinary Share on a one-for-one basis in accordance with the Plan.